APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Pain

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Pain Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchCancer Pain Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Pain Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Cancer Pain Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Pain Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Pain Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Pain market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Pain market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Pain market include Teva pharmaceuticals, Sanofi, Johnson＆Johnson, Eli-Lilly, WEX Pharmaceuticals, ProStrakan Group, Orexo, Meda Pharmaceuticals and GW Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cancer Pain market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Pain and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Pain revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cancer Pain market.

Cancer Pain Segment by Company

Teva pharmaceuticals

Sanofi

Johnson＆Johnson

Eli-Lilly

WEX Pharmaceuticals

ProStrakan Group

Orexo

Meda Pharmaceuticals

GW Pharmaceuticals

Grunenthal Group

BioDelivery Science

Cancer Pain Segment by Type

Opioids

Non-Steroidal Anti-Inflammatory Drugs

Others

Cancer Pain Segment by Application

Hormone Therapy

Chemotherapy

Radiotherapy

Others

Cancer Pain Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cancer Pain status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cancer Pain key companies, revenue, market share, and recent developments.

3. To split the Cancer Pain breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cancer Pain market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Pain significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Pain competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Pain.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Pain industry.

Chapter 3: Detailed analysis of Cancer Pain company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cancer Pain in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cancer Pain in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Pain Industry Trends Table 2. Cancer Pain Industry Drivers Table 3. Cancer Pain Industry Opportunities and Challenges Table 4. Cancer Pain Industry Restraints Table 5. Global Cancer Pain Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Pain Revenue Share by Company (2021-2026) Table 7. Global Cancer Pain Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cancer Pain Key Company Manufacturing Base & Headquarters Table 9. Global Cancer Pain Company, Product Type & Application Table 10. Global Cancer Pain Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cancer Pain by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Opioids Table 15. Significant Companies of Non-Steroidal Anti-Inflammatory Drugs Table 16. Significant Companies of Others Table 17. Global Cancer Pain Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Cancer Pain Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Cancer Pain Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Cancer Pain Sales Value Share by Type (2021-2026) Table 21. Global Cancer Pain Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hormone Therapy Table 23. Significant Companies of Chemotherapy Table 24. Significant Companies of Radiotherapy Table 25. Significant Companies of Others Table 26. Global Cancer Pain Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cancer Pain Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Cancer Pain Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Cancer Pain Sales Value Share by Application (2021-2026) Table 30. Global Cancer Pain Sales Value Share by Application (2027-2032) Table 31. Global Cancer Pain Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Cancer Pain Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Cancer Pain Sales Value Share by Region (2021-2026) Table 34. Global Cancer Pain Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Cancer Pain Sales Value Share by Region (2027-2032) Table 36. Global Cancer Pain Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Cancer Pain Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Cancer Pain Sales Value Market Share by Country (2021-2026) Table 39. Global Cancer Pain Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Cancer Pain Sales Value Market Share by Country (2027-2032) Table 41. Teva pharmaceuticals Company Information Table 42. Teva pharmaceuticals Business Overview Table 43. Teva pharmaceuticals Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Teva pharmaceuticals Cancer Pain Product Portfolio Table 45. Teva pharmaceuticals Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Sanofi Cancer Pain Product Portfolio Table 50. Sanofi Recent Development Table 51. Johnson＆Johnson Company Information Table 52. Johnson＆Johnson Business Overview Table 53. Johnson＆Johnson Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Johnson＆Johnson Cancer Pain Product Portfolio Table 55. Johnson＆Johnson Recent Development Table 56. Eli-Lilly Company Information Table 57. Eli-Lilly Business Overview Table 58. Eli-Lilly Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Eli-Lilly Cancer Pain Product Portfolio Table 60. Eli-Lilly Recent Development Table 61. WEX Pharmaceuticals Company Information Table 62. WEX Pharmaceuticals Business Overview Table 63. WEX Pharmaceuticals Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. WEX Pharmaceuticals Cancer Pain Product Portfolio Table 65. WEX Pharmaceuticals Recent Development Table 66. ProStrakan Group Company Information Table 67. ProStrakan Group Business Overview Table 68. ProStrakan Group Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. ProStrakan Group Cancer Pain Product Portfolio Table 70. ProStrakan Group Recent Development Table 71. Orexo Company Information Table 72. Orexo Business Overview Table 73. Orexo Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Orexo Cancer Pain Product Portfolio Table 75. Orexo Recent Development Table 76. Meda Pharmaceuticals Company Information Table 77. Meda Pharmaceuticals Business Overview Table 78. Meda Pharmaceuticals Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Meda Pharmaceuticals Cancer Pain Product Portfolio Table 80. Meda Pharmaceuticals Recent Development Table 81. GW Pharmaceuticals Company Information Table 82. GW Pharmaceuticals Business Overview Table 83. GW Pharmaceuticals Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GW Pharmaceuticals Cancer Pain Product Portfolio Table 85. GW Pharmaceuticals Recent Development Table 86. Grunenthal Group Company Information Table 87. Grunenthal Group Business Overview Table 88. Grunenthal Group Cancer Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Grunenthal Group Cancer Pain Product Portfolio Table 90. Grunenthal Group Recent Development Table 91. BioDelivery Science Company Information Table 92. BioDelivery Science Business Overview Table 93. BioDelivery Science Cancer Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. BioDelivery Science Cancer Pain Product Portfolio Table 95. BioDelivery Science Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Cancer Pain Product Image Figure 2. Global Cancer Pain Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Pain Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Pain Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Opioids Image Figure 8. Non-Steroidal Anti-Inflammatory Drugs Image Figure 9. Others Image Figure 10. Global Cancer Pain Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Cancer Pain Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Cancer Pain Sales Value Share by Type (2021-2032) Figure 13. Hormone Therapy Image Figure 14. Chemotherapy Image Figure 15. Radiotherapy Image Figure 16. Others Image Figure 17. Global Cancer Pain Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Cancer Pain Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Cancer Pain Sales Value Share by Application (2021-2032) Figure 20. Global Cancer Pain Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Cancer Pain Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Cancer Pain Sales Value (2021-2032) & (US$ Million) Figure 23. North America Cancer Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Cancer Pain Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Cancer Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Cancer Pain Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Cancer Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Cancer Pain Sales Value (2021-2032) & (US$ Million) Figure 29. South America Cancer Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Cancer Pain Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Cancer Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Cancer Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Cancer Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Cancer Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Opioids
  • Non-Steroidal Anti-Inflammatory Drugs
  • Others
Applications
  • Hormone Therapy
  • Chemotherapy
  • Radiotherapy
  • Others
Companies covered
  • Teva pharmaceuticals
  • Sanofi
  • Johnson＆Johnson
  • Eli-Lilly
  • WEX Pharmaceuticals
  • ProStrakan Group
  • Orexo
  • Meda Pharmaceuticals
  • GW Pharmaceuticals
  • Grunenthal Group
  • BioDelivery Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Pain Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Pain Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cancer Pain Market Dynamics
  1. 2.1 Cancer Pain Industry Trends
  2. 2.2 Cancer Pain Industry Drivers
  3. 2.3 Cancer Pain Industry Opportunities and Challenges
  4. 2.4 Cancer Pain Industry Restraints
3 Cancer Pain Market by Company
  1. 3.1 Global Cancer Pain Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Pain Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Pain Company Ranking (2024-2026)
  4. 3.4 Global Cancer Pain Company Manufacturing Base and Headquarters
  5. 3.5 Global Cancer Pain Company Product Type and Application
  6. 3.6 Global Cancer Pain Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cancer Pain Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cancer Pain Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cancer Pain Market by Type
  1. 4.1 Cancer Pain Type Introduction
  2. 4.1.1 Opioids
  3. 4.1.2 Non-Steroidal Anti-Inflammatory Drugs
  4. 4.1.3 Others
  5. 4.2 Global Cancer Pain Sales Value by Type
  6. 4.2.1 Global Cancer Pain Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Cancer Pain Sales Value by Type (2021-2032)
  8. 4.2.3 Global Cancer Pain Sales Value Share by Type (2021-2032)
5 Cancer Pain Market by Application
  1. 5.1 Cancer Pain Application Introduction
  2. 5.1.1 Hormone Therapy
  3. 5.1.2 Chemotherapy
  4. 5.1.3 Radiotherapy
  5. 5.1.4 Others
  6. 5.2 Global Cancer Pain Sales Value by Application
  7. 5.2.1 Global Cancer Pain Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cancer Pain Sales Value by Application (2021-2032)
  9. 5.2.3 Global Cancer Pain Sales Value Share by Application (2021-2032)
6 Cancer Pain Regional Value Analysis
  1. 6.1 Global Cancer Pain Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Pain Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cancer Pain Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cancer Pain Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Pain Sales Value (2021-2032)
  7. 6.3.2 North America Cancer Pain Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cancer Pain Sales Value (2021-2032)
  10. 6.4.2 Europe Cancer Pain Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cancer Pain Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cancer Pain Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cancer Pain Sales Value (2021-2032)
  16. 6.6.2 South America Cancer Pain Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cancer Pain Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cancer Pain Sales Value Share by Country, 2025 VS 2032
7 Cancer Pain Country-level Value Analysis
  1. 7.1 Global Cancer Pain Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Pain Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cancer Pain Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cancer Pain Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cancer Pain Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cancer Pain Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cancer Pain Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cancer Pain Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cancer Pain Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cancer Pain Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cancer Pain Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cancer Pain Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cancer Pain Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cancer Pain Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cancer Pain Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cancer Pain Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cancer Pain Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cancer Pain Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cancer Pain Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cancer Pain Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cancer Pain Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cancer Pain Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cancer Pain Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cancer Pain Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cancer Pain Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cancer Pain Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cancer Pain Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cancer Pain Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cancer Pain Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cancer Pain Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cancer Pain Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cancer Pain Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cancer Pain Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cancer Pain Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cancer Pain Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cancer Pain Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cancer Pain Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cancer Pain Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cancer Pain Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cancer Pain Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cancer Pain Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cancer Pain Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cancer Pain Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cancer Pain Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cancer Pain Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cancer Pain Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cancer Pain Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cancer Pain Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cancer Pain Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cancer Pain Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cancer Pain Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cancer Pain Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cancer Pain Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cancer Pain Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cancer Pain Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cancer Pain Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cancer Pain Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cancer Pain Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cancer Pain Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cancer Pain Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cancer Pain Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cancer Pain Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cancer Pain Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cancer Pain Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cancer Pain Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cancer Pain Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cancer Pain Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cancer Pain Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cancer Pain Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cancer Pain Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cancer Pain Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cancer Pain Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cancer Pain Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cancer Pain Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cancer Pain Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cancer Pain Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cancer Pain Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cancer Pain Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cancer Pain Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cancer Pain Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cancer Pain Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cancer Pain Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cancer Pain Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cancer Pain Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cancer Pain Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cancer Pain Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cancer Pain Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cancer Pain Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva pharmaceuticals
  2. 8.1.1 Teva pharmaceuticals Company Information
  3. 8.1.2 Teva pharmaceuticals Business Overview
  4. 8.1.3 Teva pharmaceuticals Cancer Pain Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva pharmaceuticals Cancer Pain Product Portfolio
  6. 8.1.5 Teva pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Cancer Pain Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Cancer Pain Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson＆Johnson
  14. 8.3.1 Johnson＆Johnson Company Information
  15. 8.3.2 Johnson＆Johnson Business Overview
  16. 8.3.3 Johnson＆Johnson Cancer Pain Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson＆Johnson Cancer Pain Product Portfolio
  18. 8.3.5 Johnson＆Johnson Recent Developments
  19. 8.4 Eli-Lilly
  20. 8.4.1 Eli-Lilly Company Information
  21. 8.4.2 Eli-Lilly Business Overview
  22. 8.4.3 Eli-Lilly Cancer Pain Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli-Lilly Cancer Pain Product Portfolio
  24. 8.4.5 Eli-Lilly Recent Developments
  25. 8.5 WEX Pharmaceuticals
  26. 8.5.1 WEX Pharmaceuticals Company Information
  27. 8.5.2 WEX Pharmaceuticals Business Overview
  28. 8.5.3 WEX Pharmaceuticals Cancer Pain Revenue and Gross Margin (2021-2026)
  29. 8.5.4 WEX Pharmaceuticals Cancer Pain Product Portfolio
  30. 8.5.5 WEX Pharmaceuticals Recent Developments
  31. 8.6 ProStrakan Group
  32. 8.6.1 ProStrakan Group Company Information
  33. 8.6.2 ProStrakan Group Business Overview
  34. 8.6.3 ProStrakan Group Cancer Pain Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProStrakan Group Cancer Pain Product Portfolio
  36. 8.6.5 ProStrakan Group Recent Developments
  37. 8.7 Orexo
  38. 8.7.1 Orexo Company Information
  39. 8.7.2 Orexo Business Overview
  40. 8.7.3 Orexo Cancer Pain Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Orexo Cancer Pain Product Portfolio
  42. 8.7.5 Orexo Recent Developments
  43. 8.8 Meda Pharmaceuticals
  44. 8.8.1 Meda Pharmaceuticals Company Information
  45. 8.8.2 Meda Pharmaceuticals Business Overview
  46. 8.8.3 Meda Pharmaceuticals Cancer Pain Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Meda Pharmaceuticals Cancer Pain Product Portfolio
  48. 8.8.5 Meda Pharmaceuticals Recent Developments
  49. 8.9 GW Pharmaceuticals
  50. 8.9.1 GW Pharmaceuticals Company Information
  51. 8.9.2 GW Pharmaceuticals Business Overview
  52. 8.9.3 GW Pharmaceuticals Cancer Pain Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GW Pharmaceuticals Cancer Pain Product Portfolio
  54. 8.9.5 GW Pharmaceuticals Recent Developments
  55. 8.10 Grunenthal Group
  56. 8.10.1 Grunenthal Group Company Information
  57. 8.10.2 Grunenthal Group Business Overview
  58. 8.10.3 Grunenthal Group Cancer Pain Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Grunenthal Group Cancer Pain Product Portfolio
  60. 8.10.5 Grunenthal Group Recent Developments
  61. 8.11 BioDelivery Science
  62. 8.11.1 BioDelivery Science Company Information
  63. 8.11.2 BioDelivery Science Business Overview
  64. 8.11.3 BioDelivery Science Cancer Pain Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BioDelivery Science Cancer Pain Product Portfolio
  66. 8.11.5 BioDelivery Science Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst